Cell-mediated Immunity versus tumor antigens (cytosols) of the same histotype and site was evaluated by means of the leukocyte adherence Inhibition (LAI) test in 44 colorectal adenocarcinoma and 17 lung squamous-cell carcinoma patients 3–10 years after surgical resection. LAI-positivity was observed in 17/44 (38.6 %) and 13/17 (76.5 %) patients, respectively, together with serum blocking factors in 7/17 (41.2%) compared to 0/13. These results indicate that a high percentage of long survivors retain an immunologic memory of the tumor antigen to which they have been exposed. The prognostic significance of serum blocking factors is less clear.
Get full access to this article
View all access options for this article.
References
1.
BernerY.: Diagnostic value of the computerized tube LAI assay for human colorectal breast and lung cancer. Oncology, 43: 327–334, 1986.
2.
BrayA.E., HoltP.G.: Serum blocking factor as an index of metastatic spread following primary tumor excision. Eur. J. Cancer, 11: 855–860, 1975.
3.
FazioM., NegriL., MastromatteoV., PacchioniD., CalabreseF., GiacomassoS.: Treatment of cancer patients with autologous lymphocytes pre-incubated with T.F. from long survivors. J. Exp. Pathol., 3: 569–577, 1987.
4.
FazioM., VergnanoF., CavalleroP., SartorisS.: Studio in vitro dell'azione di sieri di pazienti carcinomatosi nella blastizzazione linfocitaria. Boll. Soc. It. Biol. Sper., 53: 1894–1897, 1977.
FudenbergH.H., FudenbergH.H.: Transfer Factor: past, present and future. Annu. Rev. Pharmacol. Toxicol., 29: 475–516, 1989.
7.
HallidayW.J., KoppiT.A., KhanJ.M., DavisN.C.: Leukocyte adherence inhibition: tumor specificity of cellular and serum blocking reactions in human melanoma, breast cancer, and colorectal cancer. J.N.C.I., 65: 327–335, 1980.
8.
HallidayW.J., MaluishA.E., LittleJ.H., DavisN.C.: Leukocyte adherence inhibition and specific immunoreactivity in malignant melanoma. Int. J. Cancer, 16: 645–658, 1975.
9.
HallidayW.J., MaluishA.E., StephensonP.M., DavisN.C.: An evaluation of leukocyte adherence inhibition in the immunodiagnosis of colorectal cancer. Cancer Res., 37: 1962–1971, 1977.
10.
HallidayW.J., MillerS.: Leukocyte adherence inhibition: a simple test for cell-mediated tumor immunity and serum blocking factors. Int. J. Cancer, 9: 447–483, 1972.
11.
HellströmK.E., HellströmI.: The need to establish whether the leukocyte adherence inhibition test is a reliable assay of tumor immunity in humans. Cancer Res., 39: 649–650, 1979.
12.
HoltP.G., FimmelP.J., Finlay-JonesL.M., FlowerR.L.: Evaluation of the microplate leukocyte adherence inhibition test and its reproducibility, sensitivity, and relationship to other tests of cellular immunity. Cancer Res., 39: 564–569, 1979.
13.
HorvathM.: Humoral LAI (H-LAI) before and after surgery in human breast cancer. Neoplasma, 32: 623–627, 1985.
14.
HowellJ.H.: Current status of leukocyte adherence inhibition. Cancer Res., 39: 556–557, 1979.
15.
KotlarH.K., EkerP., BrennhovdI., HostH., HoieJ., SannerT.: Leukocyte adherence inhibition assay in human pulmonary neoplasia. Eur. J. Cancer Clin. Oncol., 18: 141–146, 1982.
16.
LiuH.P., YanZ.S., ZhangS.S.: The application of LAI assay to patients with colorectal cancer. Comparison with serum level of CEA, ANA and sialic acid. Dis. Colon Rectum, 32: 210–213, 1989.
17.
MaluishA.E.: Experiences with leukocyte adherence inhibition in human cancer. Cancer Res., 39: 644–648, 1979.
18.
MartiJ.H., ThomsonD.M.P.: Anti-tumor immunity in malign melanoma assay by tube leukocyte adherence inhibition. Cancer, 34: 116–133, 1976.
19.
PowellA.E., SlossA.M., SmithR.N., MakleyJ.T., HubayC.A.: Specific responsiveness of leukocytes to soluble extracts of human tumors. Int. J. Cancer, 16: 905–913, 1975.
20.
ThomsonD.M.P., SpringerG.F., DesaiP.R., ScanzanoR., GuberskyM., ShenoudaG.: Comparison by LAI of human immune response to cancer-associated immunogens, Thomsen-Friedenreich (T) and Tn, myelinic basic protein, and organ-specific cancer neoantigens. Clin. Immunol. Immunopathol., 49: 231–241, 1988.
21.
TsangP.M.: Effector lymphocyte response to homologous tumor antigens in various stages of malignant diseases as monitored by LAI cell-mediated immunity (LAI-CMI). Immunol. Lett., 17: 63–70, 1988.
22.
YonemotoR.H., FujisawaT., WaldmanS.R.: Effect of serum blocking factors on leukocyte adherence inhibition in breast cancer patients. Cancer, 41: 1289–1297, 1978.
